Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

Home
/
update
/
details

OncoLens Introduces Real-Time Oncology Patient Identification for Clinical Trials and Essential Services

NextEdge Admin

19 Sep 2024

2 min 25 sec

digital health solutions,clinical trials

OncoLens provides innovative digital health solutions aimed at delivering the right cancer treatment at the right time through three core pillars: data interoperability, multidisciplinary collaboration, and actionable informatics. By integrating data from various sources such as electronic medical records (EMR) and lab results, OncoLens identifies key patterns in patient clinical information. This integration generates real-time alerts for healthcare teams, helping identify patients who match clinical trial criteria, qualify for advanced therapies like CAR-T, or may have missed critical biomarker testing.

As cancer care becomes increasingly complex with the rise of hyper-targeted therapies and shifting guidelines, healthcare providers face challenges in ensuring patients receive optimal care. Large healthcare systems also grapple with patient leakage, where patients are referred out of the system rather than directed to in-house resources. Clinical trial enrollment is particularly affected, with Principal Investigators struggling to identify and enroll eligible patients.

OncoLens addresses these issues by utilizing AI, NLP, and its oncology-focused knowledge model to deliver timely reports and alerts. Its suite of tools, including OncoLens Conference and Collaborate, helps care teams track patients effectively and ensures timely sharing of information through tumor boards.

OncoLens’ solutions have proven effective in identifying patients who have missed essential germline or somatic testing, reducing time to treatment, and aligning with value-based healthcare models. With over 225 cancer centers in the U.S. and international collaborations, OncoLens also works with pharmaceutical and diagnostic companies through its Research Network to connect cancer centers with industry partners.